Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Amadeo, B"'
Autor:
Akhave NS; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Biter AB; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hong DS; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Publikováno v:
Molecular cancer therapeutics [Mol Cancer Ther] 2022 Nov 03; Vol. 21 (11), pp. 1645-1651.
Autor:
Akhave NS; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Biter AB; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hong DS; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas. dshong@mdanderson.org.
Publikováno v:
Cancer discovery [Cancer Discov] 2021 Jun; Vol. 11 (6), pp. 1345-1352. Date of Electronic Publication: 2021 Apr 05.
Autor:
Thein KZ; Division of Hematology and Medical Oncology, Oregon Health and Science University/Knight Cancer Institute, Portland, Oregon 97239, USA; email: theink@ohsu.edu., Biter AB; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA; email: abbiter@mdanderson.org, dshong@mdanderson.org., Hong DS; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA; email: abbiter@mdanderson.org, dshong@mdanderson.org.
Publikováno v:
Annual review of medicine [Annu Rev Med] 2021 Jan 27; Vol. 72, pp. 349-364. Date of Electronic Publication: 2020 Nov 02.
Publikováno v:
Mol Cancer Ther
The development of selective KRASG12C inhibitors that directly inhibit KRAS, an oncogene historically thought to be “undruggable,” represents a watershed moment in oncology and developmental therapeutics. Now, as KRAS-targeted therapy moves into
Autor:
Kyaw Z, Thein, Amadeo B, Biter, Kimberly C, Banks, Andrew W, Duda, Jennifer, Saam, Jason, Roszik, Filip, Janku, Ferdinandos, Skoulidis, John V, Heymach, Scott, Kopetz, Funda, Meric-Bernstam, David S, Hong
Publikováno v:
JCO precision oncology. 6
We conducted a 5-year retrospective review ofOur study demonstrates the feasibility of using circulating tumor DNA to identify
Publikováno v:
Cancer Discov
KRAS mutations are among the most common drivers of human carcinogenesis, and are associated with poor prognosis and an aggressive disease course. With the advent of KRAS(G12C) inhibitors, the RAS protein is now targetable, with such inhibitors showi
Publikováno v:
Annual review of medicine. 72
Aberrations in rat sarcoma (RAS) viral oncogene are the most prevalent and best-known genetic alterations identified in human cancers. Indeed, RAS drives tumorigenesis as one of the downstream effectors of EGFR activation, regulating cellular switche